R D Blumenthal

Summary

Country: USA

Publications

  1. ncbi request reprint Unique molecular markers in human endometriosis: implications for diagnosis and therapy
    R D Blumenthal
    Garden State Cancer Center, 520 Belleville Avenue, Belleville, NJ 07109, USA
    Expert Rev Mol Med 3:1-12. 2001
  2. ncbi request reprint Chronotherapy and chronotoxicity of the cyclooxygenase-2 inhibitor, celecoxib, in athymic mice bearing human breast cancer xenografts
    R D Blumenthal
    Garden State Cancer Center, Belleville, New Jersey 07109, USA
    Clin Cancer Res 7:3178-85. 2001
  3. ncbi request reprint Modulation of marrow proliferation and chemosensitivity by tumor-produced cytokines from syngeneic pancreatic tumor lines
    Rosalyn D Blumenthal
    Garden State Cancer Center, Belleville, New Jersey 07109, USA
    Clin Cancer Res 8:1301-9. 2002
  4. ncbi request reprint Optimizing the use of combined radioimmunotherapy and hypoxic cytotoxin therapy as a function of tumor hypoxia
    R D Blumenthal
    Garden State Cancer Center, Belleville, NJ 07109, USA
    Int J Cancer 94:564-71. 2001
  5. ncbi request reprint Anti-oxidant vitamins reduce normal tissue toxicity induced by radio-immunotherapy
    R D Blumenthal
    Garden State Cancer Center, Belleville, NJ 07109, USA
    Int J Cancer 86:276-80. 2000
  6. ncbi request reprint Application of cytokine intervention for improved radio-antibody dose delivery
    R D Blumenthal
    Garden State Cancer Center at the Center for Molecular Medicine and Immunology, Belleville, NJ 07109, USA
    Int J Cancer 72:166-73. 1997
  7. ncbi request reprint Chronotolerance of experimental radioimmunotherapy: clearance, toxicity, and maximal tolerated dose of 131I-anti-carcinoembryonic antigen (CEA) IgG as a function of time of day of dosing in a murine model
    R D Blumenthal
    Garden State Cancer Center, Belleville, New Jersey, USA
    Eur J Cancer 35:815-24. 1999
  8. ncbi request reprint Regulation of tumour drug delivery by blood flow chronobiology
    R D Blumenthal
    Garden State Cancer Center, 520 Belleville Avenue, 07109, Belleville, NJ, USA
    Eur J Cancer 36:1876-84. 2000
  9. ncbi request reprint Changes in tumor vascular permeability in response to experimental radioimmunotherapy: a comparative study of 11 xenografts
    R D Blumenthal
    Garden State Cancer Center, Belleville, NJ 07103, USA
    Tumour Biol 18:367-77. 1997
  10. ncbi request reprint Importance of timing of radioimmunotherapy after granulocyte colony-stimulating factor administration for peripheral blood stem cell harvest
    M E Juweid
    Garden State Cancer Center, Belleville, New Jersey 07109, USA
    Clin Cancer Res 5:3337s-3342s. 1999

Detail Information

Publications25

  1. ncbi request reprint Unique molecular markers in human endometriosis: implications for diagnosis and therapy
    R D Blumenthal
    Garden State Cancer Center, 520 Belleville Avenue, Belleville, NJ 07109, USA
    Expert Rev Mol Med 3:1-12. 2001
    ..EPO targeting using this antibody could be useful for detecting and/or treating endometriosis...
  2. ncbi request reprint Chronotherapy and chronotoxicity of the cyclooxygenase-2 inhibitor, celecoxib, in athymic mice bearing human breast cancer xenografts
    R D Blumenthal
    Garden State Cancer Center, Belleville, New Jersey 07109, USA
    Clin Cancer Res 7:3178-85. 2001
    ..Therefore, we examined the time dependence of toxicity (chronotoxicity) and of antitumor effects (chronotherapy) of celecoxib to determine optimal time of day for dosing with respect to light-dark cycles...
  3. ncbi request reprint Modulation of marrow proliferation and chemosensitivity by tumor-produced cytokines from syngeneic pancreatic tumor lines
    Rosalyn D Blumenthal
    Garden State Cancer Center, Belleville, New Jersey 07109, USA
    Clin Cancer Res 8:1301-9. 2002
    ..We postulate that an excess of tumor-produced stimulatory or inhibitory cytokines could impact marrow proliferation and sensitivity to cytotoxic agents...
  4. ncbi request reprint Optimizing the use of combined radioimmunotherapy and hypoxic cytotoxin therapy as a function of tumor hypoxia
    R D Blumenthal
    Garden State Cancer Center, Belleville, NJ 07109, USA
    Int J Cancer 94:564-71. 2001
    ..Thus, information on tumor hypoxia after radioantibody therapy could be important for ascertaining a window of opportunity when the surviving tumor regions are most responsive to hypoxic cytotoxins...
  5. ncbi request reprint Anti-oxidant vitamins reduce normal tissue toxicity induced by radio-immunotherapy
    R D Blumenthal
    Garden State Cancer Center, Belleville, NJ 07109, USA
    Int J Cancer 86:276-80. 2000
    ..On day 14 after the 400 microCi dose of RAIT (day 7 post-BMT), the additive effect of BMT and vitamin could be detected. Tumor growth was not adversely affected by vitamin administration...
  6. ncbi request reprint Application of cytokine intervention for improved radio-antibody dose delivery
    R D Blumenthal
    Garden State Cancer Center at the Center for Molecular Medicine and Immunology, Belleville, NJ 07109, USA
    Int J Cancer 72:166-73. 1997
    ..However, cytokines were not effective at permitting dose escalation of either 90Y-F(ab')2 or 188Re-IgG. Further optimization of the dose schedule of cytokine administration needs to be explored for these 2 nuclide-antibody forms...
  7. ncbi request reprint Chronotolerance of experimental radioimmunotherapy: clearance, toxicity, and maximal tolerated dose of 131I-anti-carcinoembryonic antigen (CEA) IgG as a function of time of day of dosing in a murine model
    R D Blumenthal
    Garden State Cancer Center, Belleville, New Jersey, USA
    Eur J Cancer 35:815-24. 1999
    ..These studies suggest that principles of chronobiology may govern the magnitude of toxicity and the highest dose tolerated in radioantibody therapy in the same way that it does for cytotoxic drug therapy...
  8. ncbi request reprint Regulation of tumour drug delivery by blood flow chronobiology
    R D Blumenthal
    Garden State Cancer Center, 520 Belleville Avenue, 07109, Belleville, NJ, USA
    Eur J Cancer 36:1876-84. 2000
    ..48+/-0.81 (P<0.01). These results suggest that small shifts in the chronobiology of BF in tumour and in normal tissue can have a sizeable impact on the distribution of chemotherapeutics and antibody-based drugs...
  9. ncbi request reprint Changes in tumor vascular permeability in response to experimental radioimmunotherapy: a comparative study of 11 xenografts
    R D Blumenthal
    Garden State Cancer Center, Belleville, NJ 07103, USA
    Tumour Biol 18:367-77. 1997
    ..Administration of arginine, a substrate for nitric oxide synthase, results in increases in both baseline and RAIT-modified VP in GW-39 and ME-180 tumors...
  10. ncbi request reprint Importance of timing of radioimmunotherapy after granulocyte colony-stimulating factor administration for peripheral blood stem cell harvest
    M E Juweid
    Garden State Cancer Center, Belleville, New Jersey 07109, USA
    Clin Cancer Res 5:3337s-3342s. 1999
    ....
  11. ncbi request reprint Tumor-specific dose scheduling of bimodal radioimmunotherapy and chemotherapy
    R D Blumenthal
    Garden State Cancer Center, Center for Molecular Medicine and Immunology, Belleville, NJ 07109, USA
    Anticancer Res 23:4613-9. 2003
    ..We postulated that the agents and dose scheduling of bimodal RAIT plus chemotherapy might have to be tailored to each tumor based on the expression of specific relevant genes...
  12. ncbi request reprint Colonic tumor CEA, CSAp and MUC-1 expression following radioimmunotherapy or chemotherapy
    D E Modrak
    Garden State Cancer Center, Belleville, NJ 07109, USA
    Tumour Biol 24:32-9. 2003
    ..Thus, these data indicate that the response of tumor cells to low-dose-rate radiation from RAIT or to chemotherapy is associated with an increase of CEA, MUC-1 and CSAp...
  13. ncbi request reprint An in vitro model to optimize dose scheduling of multimodal radioimmunotherapy and chemotherapy: effects of p53 expression
    Rosalyn D Blumenthal
    Garden State Cancer Center, Belleville, NJ 07109, USA
    Int J Cancer 108:293-300. 2004
    ....
  14. ncbi request reprint Altered tumor vessel maturation and proliferation in placenta growth factor-producing tumors: potential relationship to post-therapy tumor angiogenesis and recurrence
    Alice P Taylor
    Garden State Cancer Center, Center for Molecular Medicine and Immunology, Belleville, NJ, USA
    Int J Cancer 105:158-64. 2003
    ..Prevention of this angiogenic response to treatment may require administration of anti-angiogenic therapy during, rather than after, treatment...
  15. ncbi request reprint Tumor-specific regulation of angiogenic growth factors and their receptors during recovery from cytotoxic therapy
    Alice P Taylor
    Tumor Biology, Garden State Cancer Center, Belleville, New Jersey 07109, USA
    Clin Cancer Res 8:1213-22. 2002
    ..Antiangiogenic therapy may require a tumor-specific combination of inhibitors for PlGF, the angiopoietins, or their receptors, in addition to VEGF/flk-1...
  16. ncbi request reprint Celecoxib exhibits the greatest potency amongst cyclooxygenase (COX) inhibitors for growth inhibition of COX-2-negative hematopoietic and epithelial cell lines
    Chris Waskewich
    Garden State Cancer Center, Belleville, New Jersey 07109, USA
    Cancer Res 62:2029-33. 2002
    ....
  17. ncbi request reprint Sphingomyelin enhances chemotherapy efficacy and increases apoptosis in human colonic tumor xenografts
    David E Modrak
    Garden State Cancer Center, Belleville, NJ 07109, USA
    Int J Oncol 20:379-84. 2002
    ..Furthermore, this enhancement may be due to a reversal of the attenuation of the apoptotic signal found in cancer cells without inducing significant hematopoietic, hepatic or renal toxicity...
  18. ncbi request reprint Carcinoembryonic antigen antibody inhibits lung metastasis and augments chemotherapy in a human colonic carcinoma xenograft
    Rosalyn D Blumenthal
    Center for Molecular Medicine and Immunology, Garden State Cancer Center, 520 Belleville Avenue, Belleville, NJ 07109, USA
    Cancer Immunol Immunother 54:315-27. 2005
    ..However, it is not known if treatment with anti-CEA antibodies can affect tumor metastasis or alter the effects of cytotoxic drugs...
  19. ncbi request reprint Peroxisome proliferator-activated receptor-gamma antagonists exhibit potent antiproliferative effects versus many hematopoietic and epithelial cancer cell lines
    Jack D Burton
    Center for Molecular Medicine and Immunology, Belleville, New Jersey 07109, USA
    Anticancer Drugs 18:525-34. 2007
    ..These findings support further translational studies to explore the mechanism of action and therapeutic potential of this class of agents...
  20. ncbi request reprint Inhibition of adhesion, invasion, and metastasis by antibodies targeting CEACAM6 (NCA-90) and CEACAM5 (Carcinoembryonic Antigen)
    Rosalyn D Blumenthal
    Center for Molecular Medicine and Immunology, Garden State Cancer Center, Belleville, New Jersey 07109, USA
    Cancer Res 65:8809-17. 2005
    ..Thus, blocking the N and A1B1 domains of CEACAM5/CEACAM6 can impede the metastatic process...
  21. ncbi request reprint An overview of chemosensitivity testing
    Rosalyn D Blumenthal
    Garden State Cancer Center, Belleville, NJ, USA
    Methods Mol Med 110:3-18. 2005
    ..The advantages and disadvantages of the specific assays are discussed. A summary of research areas related to chemo sensitivity testing is also included...
  22. ncbi request reprint Technology evaluation: Onyvax-105, Onyvax
    Rosalyn D Blumenthal
    Garden State Cancer Center, 520 Belleville Avenue, Belleville, NJ 07109, USA
    Curr Opin Mol Ther 5:668-72. 2003
    ..Onyvax, under license from the Cancer Research Campaign, is developing Onyvax-105 (105AD7), an anti-idiotype monoclonal antibody, for the potential treatment of colorectal cancer. Onyvax initiated phase II clinical trials in May 2000...
  23. ncbi request reprint Tumor pO2 assessments in human xenograft tumors measured by EPR oximetry: location of paramagnetic materials
    JULIA A O'HARA
    Department of Diagnostic Radiology, Dartmouth Medical School, Hanover, NH, USA
    Adv Exp Med Biol 530:205-14. 2003
    ..We monitored tumor pO2 during growth and also examined the tumor histological structure overall and in the region of the paramagnetic material in the tumor at the time of necropsy...
  24. ncbi request reprint Red marrow radiation dose adjustment using plasma FLT3-L cytokine levels: improved correlations between hematologic toxicity and bone marrow dose for radioimmunotherapy patients
    Jeffry A Siegel
    Nuclear Physics Enterprises, Cherry Hill, New Jersey 08003, USA
    J Nucl Med 44:67-76. 2003
    ....
  25. ncbi request reprint Advantage of combining NLCQ-1 (NSC 709257) with radiation in treatment of human head and neck xenografts
    Maria V Papadopoulou
    Department of Radiation Medicine, Evanston Northwestern Healthcare, Evanston, Illinois 60201, USA
    Radiat Res 168:65-71. 2007
    ..These results suggest a significant advantage in combining radiation with NLCQ-1 in treatment of human head and neck tumors, which are known to have hypoxic areas...